Article

The Problem with the Cancer ‘Battle’

The terminology surrounding the cancer journey is often associated with a “battle” and can misconstrue the experience of treatment.

Language is an important tool when it comes to living with cancer. The terminology used when referring to an individual’s experience with the disease can incite a range of emotions and can often be misconstrued.

Dr. Mark Lewis, of Intermountain Healthcare, is also a survivor. In a recent interview with CURE®, Lewis discussed why the use of the word “battle” can be polarizing when referring to someone’s cancer journey, and why sometimes the idea of opting to forego treatment is the bravest decision of all.

Transcription:

One of the problems I have with language around cancer is, whether patients choose or not, there's often a lot of talk about ‘battle.’

In fact, in almost every obituary I saw about Chadwick Boseman mentioned him battling cancer. You know, if you accept the fighting metaphor, that's great, but it's not for everybody. And what I don't like about it is it implies some lack of courage, or spirit, when patients either die, or, quite reasonably sometimes, if they choose not to pursue chemotherapy.

Sometimes I think the bravest decision I see is someone who, against the recommendation and pressure from their family, says, ‘You know what, I've listened to you, doc, I've heard about the risks and benefits. I just want to live my life, however long that's going to be, and I want to maximize its quality.’

That, in itself, is a very courageous decision, in my opinion.

Related Videos
Image of woman.
Dr. Andreas M. Kaiser is a professor and chief of the Division of Colorectal Surgery in the Department of Surgery at City of Hope comprehensive cancer center in Duarte, California.
Dr. Guru Sonpavde emphasized the importance of better understanding how genetic mutations influence the treatment of cancer care, particularly GU cancers.
Image of woman with blonde hair.
Dr. Frederick L. Locke sat down with CURE® to discuss treatment with cema-cel in the ALPHA/ALPHA2 studies for relapsed/refractory large B-cell lymphoma.
Dr. Park sat down for an interview with CURE® to discuss the key takeaways from the 2025 Annual ASCO Genitourinary Cancers Symposium.
Treatment with cemacabtagene ansegedleucel demonstrated responses in patients with relapsed or treatment-resistant large B-cell lymphoma.
There was no evidence that CAR T directly caused secondary malignancies, despite FDA warnings, citing prior treatments as the cause, according to research.
Image of woman with black hair.
Image of man with black hair.
Related Content